Compositions for Nasal Administration of Phenothiazines
申请人:GUY David
公开号:US20100215730A1
公开(公告)日:2010-08-26
Provided herein are pharmaceutical compositions comprising phenothiazines or derivatives thereof that are formulated for nasal administration. Also provided herein are methods of utilizing the same.
The invention relates to a procedure for purifying low molecular weight polylactic acid polymers by use of reduced temperature liquid-liquid phase separation of the polymers in methanol, ethanol or isopropanol based solvents, compositions comprising the polymers and methods of using the same.
Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.
Apomorphine-containing dosage form for ameliorating male erectile dysfunction
申请人:——
公开号:US20030073715A1
公开(公告)日:2003-04-17
Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.
Injectable suspensions having improved injectability properties
申请人:Alkermes Controlled Therapeutics, Inc.
公开号:EP1754469A1
公开(公告)日:2007-02-21
Injectable compositions having improved injectability. The injectable compositions include microparticles in an aqueous injection vehicle having a viscosity of at least 20 cp at 20 °C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase viscosity of the fluid phase of the suspension to the desired level for improved injectability.
注射剂组合物具有更好的可注射性。可注射组合物包括水性注射载体中的微颗粒,该注射载体在 20 °C 时的粘度至少为 20 cp。构成悬浮液液相的注射载体粘度增加,可显著降低体内注射失败率。可注射组合物可通过将干微颗粒与水性注射载体混合形成悬浮液,然后将悬浮液与增粘剂混合,以将悬浮液流体相的粘度增加到所需水平,从而改善可注射性。